close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Achieve Life Sciences, Inc. - Common Shares (NQ:ACHV)

4.625 -0.145 (-3.04%)
Streaming Delayed Price Updated: 12:13 PM EDT, May 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Achieve Life Sciences, Inc. - Common Shares

< Previous 1 2 3 4 Next >
News headline image
Achieve (ACHV) Q1 2026 Earnings Transcript ↗
Achieve (ACHV) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Intellectual Property
News headline image
Achieve Life Sciences Q1 Earnings Call Highlights ↗
Achieve Life Sciences (NASDAQ:ACHV) used its first-quarter 2026 earnings call to outline a transition period marked by new leadership, a major financing, manufacturing changes tied to its cytisinicline... 
Via MarketBeat
Topics Earnings
ACHV Stock Surges After Achieve Life Sciences Reports Market-Beating Q1 2026 Earnings ↗
Via Chartmill
Keep an eye on the top gainers and losers in Thursday's session. ↗
Via Chartmill
Achieve Life Sciences Inc (NASDAQ:ACHV) Reports In-Line Q4 2025 Results, Announces Key Manufacturing Partnership ↗
Via Chartmill
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
Achieve Life Sciences Stock Soars On Receiving FDA Voucher For Expediting Review Of Investigational Drug In Vaping Cessation ↗
Via Stocktwits
What's going on in today's session ↗
Via Chartmill
Thursday's session: gap up and gap down stocks ↗
Via Chartmill
These stocks are moving in today's session ↗
Via Chartmill
News headline image
Hunterbrook Capital Bets Big on Achieve Life Sciences: Why a 'Toxic Tree' Could Disrupt the Multi-Billion Dollar Smoking Cessation Market
In a move that has sent ripples through the biotech sector on the final trading days of the year, Hunterbrook Capital announced a significant bullish position in Achieve Life Sciences (NASDAQ:ACHV)... 
Via MarketMinute
Topics Product Recall
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Achieve Life Sciences’ Smoking Treatment Likely To Be Approved By FDA, Says Hunterbrook ↗
The FDA is expected to rule on Achieve Life Sciences’ application seeking approval for the drug by June 20, 2026. 
Via Stocktwits
News headline image
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
News headline image
Achieve Life Sciences Inc (NASDAQ:ACHV) Stock Rises on FDA Priority Voucher News Despite Wider-Than-Expected Loss ↗
Achieve Life Sciences stock rises on positive investor reaction to its Q3 2025 earnings and a key FDA Priority Voucher for its nicotine treatment. 
Via Chartmill
News headline image
4 Biotech Stocks Lifting Off As Momentum Builds ↗
Biotech stocks have trailed the broader market this year, but more names are starting to show strength as the rally expands and major indexes reach record levels. 
Via Benzinga
News headline image
Top movers in Friday's session ↗
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Top stock movements in today's session. ↗
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Which stocks are gapping on Friday? ↗
Traders are paying attention to the gapping stocks in Friday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
News headline image
The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly. ↗
The Commissioner's National Priority Review vouchers aims to speed up the review process to just one to two months. 
Via Investor's Business Daily
News headline image
FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times ↗
The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, and other conditions. 
Via Benzinga
News headline image
Discover the top movers in Friday's pre-market session. ↗
Before the US market kicks off on Friday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
Why CSX Shares Are Trading Higher By Over 4%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program ↗
The FDA’s new National Priority Voucher pilot helps with faster drug reviews, cutting timelines from nearly a year to weeks. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Which stocks are moving before the opening bell on Monday? ↗
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
Achieve Life Sciences Inches Closer To FDA Nod For First New Quit-Smoking Drug In 20 Years ↗
HC Wainwright backs Achieve Life Sciences with a Buy rating as cytisinicline nears potential 2026 FDA approval, targeting a large smoking cessation market. 
Via Benzinga
News headline image
Achieve (ACHV) Q2 Net Loss Hits $12.7M ↗
Via The Motley Fool
News headline image
Achieve Life Sciences Inc (NASDAQ:ACHV) Reports Q2 2025 Results: Revenue in Line, Narrow EPS Beat Drives Pre-Market Gains ↗
Achieve Life Sciences reports Q2 2025 results with $0.0 revenue and -$0.37 EPS, meeting estimates. Shares rise 2.3% pre-market as focus remains on cytisinicline development for smoking cessation. 
Via Chartmill
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today